SCHEMBL5542508

SCHEMBL5542508

[c]1ccc2nc(-c3ccsc3)[nH]c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.37
KDM4E B2RXH2 7/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
RXFP1 Q9HBX9 2/20 0.37
PKN1 Q16512 2/20 0.37
PKN2 Q16513 2/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
NPC1 O15118 7/20 0.37
RAB9A P51151 7/20 0.37
GAA P10253 4/20 0.37
SMN1; SMN2 Q16637 7/20 0.36
MAPT P10636 5/20 0.36
HPGD P15428 5/20 0.36
HSD17B10 Q99714 4/20 0.36
GFER P55789 3/20 0.36
POLB P06746 3/20 0.36
GLA P06280 3/20 0.36
TP53 P04637 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543777 0.88 KDM4E (0.37) ALDH1A1KDM4EPKN1PKN2NPC1
SCHEMBL316190 0.80 ALDH1A1 (0.60) ALDH1A1KDM4EMEN1KMT2ARXFP1
SCHEMBL5885447 0.78 NPC1 (0.62) ALDH1A1KDM4EMEN1KMT2APKN1
SCHEMBL9030999 0.78 NPC1 (0.62) ALDH1A1KDM4EMEN1KMT2APKN1
SCHEMBL29002247 0.76 ALDH1A1 (0.63) ALDH1A1KDM4EMEN1KMT2ARXFP1
SCHEMBL695531 0.75 ALDH1A1 (0.59) ALDH1A1KDM4EMEN1KMT2ARXFP1
SCHEMBL5545452 0.73 ALDH1A1 (0.65) ALDH1A1KDM4EMEN1KMT2ANPC1
SCHEMBL5539351 0.71 PDGFRB (0.39) ALDH1A1KDM4EPKN1PKN2NPC1
SCHEMBL5541731 0.71 DHODH (0.39) ALDH1A1KDM4EMEN1KMT2APKN1
SCHEMBL700482 0.71 GAA (0.51) ALDH1A1KDM4EMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-102532162-A 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2012-07-04 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885KDM4E 4854/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.